Videos

Tumor board insights reveal how ctDNA-guided ESR1 testing and SERENA-6 strategies may reshape HR+ metastatic breast cancer and local therapy choices.

See how breast cancer endocrine and targeted drugs inform endometrial and ovarian care—tamoxifen, CDK4/6 combos, and T-DXd.

Effectively assessing anemia in myelofibrosis goes beyond hemoglobin levels, and should focus on symptoms, daily function, and quality of life to guide treatment.

Paul G. Richardson, MD, discusses the SUCCESSOR-2 trial of mezigdomide, carfilzomib, and dexamethasone in multiple myeloma.

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising.

Researchers launch a public immune atlas of pancreatic cancer therapy responses, allowing the public to rapidly link pancreatic cancer immunotherapy trials to immune shifts and outcomes.

Cabozantinib offers significant benefits for patients progressing on octreotide LAR, especially those with prior treatments and specific conditions.

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic overdrive.

Dr Saad explores the emerging role of radiopharmaceuticals in prostate cancer.

Medicaid expansion has boosted breast cancer survival rates, especially for Hispanic women, highlighting ACA policy impact.

Experts weigh perioperative immunotherapy delays, rapid molecular testing, ctDNA MRD and emerging ADCs shaping early-stage lung cancer care.

Dr Ghatalia discusses RETAIN-2, highlighting ctDNA analysis drawn from RETAIN-1 and RETAIN-2.

Sagar Lonial, MD, discusses the significance of the MRD end point for the ongoing priority review of iberdomide in multiple myeloma.

Using the best medication available in the frontline setting of RCC leads to optimal results.

Efficacy and safety results from the phase 1 PAnTHA study presented at 2026 ASCO GU.

Study reveals CD25 tunes tyrosine kinase signaling into a Goldilocks sweet spot, helping AML and ALL cells resist treatment and grow.

Understanding the safety profile of belzutifan (Welireg) will expand its use role in RCC.

TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, discusses the future of BPCDN treatment and how a collaborative care model should play a role in this rare disease.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores the clinical rationale for triplet regimens combining tagraxofusp-erzs (Elzonris), azacitidine (Vidaza), and ventoclax (Venclexta).

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, outlines monitoring parameters and intervention strategies required for patient safety following treatment with tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

BPDCN breakthroughs: CD123-targeting tagraxofusp and venetoclax-azacitidine combinations boost remissions, limit myelosuppression, and help reach transplant.

Spot BPDCN fast: skin-first clues, CD123/CD4/CD56 triad, mandatory CNS staging, and transplant-focused remission strategy.

Explore rising HPV-driven anal cancer burden and NCCN first-line choices, with trial data guiding chemo-immunotherapy patient selection.

Sagar Lonial, MD, discusses the evolving role of cereblon E3 ligase modulators (CELMoDs) in the treatment of multiple myeloma.

Short-course enzalutamide in recurrent prostate cancer slashes PSA, but PSMA-PET tumor volume misleads, raising overtreatment concerns.

Rahul Banerjee, MD, discusses the rationale for potential therapeutic strategies to address T-cell exhaustion following CAR T-cell therapy in multiple myeloma.

Explore the NETTER-1 study's findings on PRRT for neuroendocrine tumors, including benefits, risks, and alternative treatments like everolimus.

Two biomarkers, KIM-1 and ctDNA, may lead to the development of a prognostic tool.